Recently, the leading vaccine companyWalvaxSen BioAnnouncement of Collaboration with AI Synthetic Biology CompanyZelixirEstablish Strategic PartnershipsWith relationship.Both parties will jointly exploreApplication of Artificial Intelligence Technology in the Research, Production, and Commercialization of Human Vaccines, accelerating the technological innovation and intelligent process of the vaccine industry.
The core of this strategic cooperation between the two parties is:Apply Zelixir's world-leading bio-computation technology, which combines AI modeling with physical simulation, to Walvax's human vaccine research and development field.Key areas include utilizing AI technology to accelerate the discovery and design of proteins (including enzymes) and other process development, providing AI biocomputing platform licensing services to build intelligent R&D infrastructure, and offering deeply customized AI biocomputing solutions tailored to the specific needs of vaccine products.Trillion-Dollar Synthetic Biology Blue Ocean: The Second Half of the Vaccine WarAccording to McKinsey's forecast, 60% of material products in future global economic activities can be produced by biotechnology. Between 2030 and 2040, synthetic biotechnology will bring annual benefits to the world.$2 trillion to $4 trillionDirect economic benefits.And this blue ocean market is actually closely related to vaccines, such asCodon optimization technology, genetically encodable click chemistry technology, bioconjugation technologyThe applications in the development of new vaccines are already very widespread.For example, known for developing the COVID-19 vaccine,Moderna was often categorized in its early years asSynthetic biology enterprises, becauseThe common principle of RNA vaccines, whole gene synthesis + codon optimization, actually belongs to a type of synthetic biology method.The application of synthetic biotechnology in designing antigens, developing novel adjuvants, and optimizing vaccine production processes will help enhance the immunogenicity, broad-spectrum efficacy, and longevity of vaccines, enriching the means of vaccine development.In addition, in the currently highly popularTumor Vaccine Field, Synthetic biology is alsoOne of the important tools in research, afterThe modified microorganisms are better adapted to the tumor microenvironment, enhance the presentation of tumor antigens, and induce multiple innate and adaptive anti-tumor immune responses.Especially some vaccines themselves are living organisms modified by synthetic biology, such asLive Attenuated Bacterial Vaccine BCGAmong them, the attenuated bacterial vaccine BCG, which is used to prevent pediatric encephalitis and tuberculosis, has been clinically applied for the treatment of bladder cancer for over 50 years.Whether it is the rapid design and construction of synthetic genes or the study of synthetic viral genomes, it canEnable enterprises to develop safer, more efficient, and broader-spectrum virus vaccines in a shorter time.Many Leading Vaccine Companies Have Embraced Synthetic BiologyWalvax relies onFocusIn the competition of bivalent HPV vaccines, there is also a "volume" in vaccines"King" of its field, with its main products such as the 13-valent pneumococcal polysaccharide conjugate vaccine continuing to maintain the largest market share in China.In response to the current industry cycle and changes in the competitive market environment, the company has chosen toThe chronic disease management of intestinal cornerstone microbiota and synthetic biological manufacturing will be the key new track for the company's future development.Apart from Walvax, in ChinaNumerous vaccine giants both in China and abroad have launched research related to synthetic biology:For example, the mRNA leaderModernaWith the synthetic biology giantGinkgo BioworksAs early as 2020, the cooperation was initiated, successfully increasing the production of Vaccinia Capping Enzyme (VCE) by 10 times.
In ChinaIn China,Yuguan BiotechFocused on the development of bacterial vaccinesSynthetic Biology Company, utilizing the self-developed PathX pathogen genome editing platform, has established 9+ innovative bacterial vaccine pipelines.
Among themSynthetic Biology Vaccine for Methicillin-Resistant Staphylococcus Aureus (MRSA)DX-101 has completed preclinical proof-of-concept, with data superior to similar products.Notably, the company also collaborated withZhilfe BioA wholly-owned subsidiary, Beijing Zhifei Green Bamboo, has reached a cooperation.And in the veterinary drug leaderRippon BiotechAlso focusing on the main business in the near futureMentioned below,AroundVeterinary vaccines, antibody drugs, enzyme preparations,Probiotics, Veterinary Drug Ingredients, Additive Ingredients, Related IntermediatesKey areas such asActively develop new business models in synthetic biology.SynthesisThe Application of Biology in the Development of Broad-Spectrum Vaccines for COVID-19.Weifeng Yuan, Yongliang Zhao, Zhixuan Wu, Ke Xu
Application of Synthetic Biology in the Design of Tumor Vaccines Based on Microbial Vectors. Tan Zibin, Liang Kang, Chen Youhai.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)